Sector Expert: Ori Hershkovitz
Ori Hershkovitz has been with the Sphera Fund since 2006, and serves as managing partner and head of pharmaceutical research. From 2001–2006 he was with Leader & Co. Investment House, where he was Israel senior pharmaceutical equity analyst. Between 1998–2001 Hershkovitz was an equity analyst at Ilanot Batucha Investment House. Hershkovitz has a bachelor's degree in business administration and finance from Tel Aviv University.
Sometimes speaking with investors who work half a world away is just what's needed to get a new angle and hear new names. That was the case when we talked with Ori Hershkovitz, managing partner of the Tel Aviv-based Sphera Global Healthcare Fund. His interest in global markets, following the news flow on his holdings and scouring the earth for new ideas, means Hershkovitz both keeps crazy hours and finds unique prospects. In this interview with The Life Sciences Report, Hershkovitz talks about his favorite names in the biotech space and lays out his growth theory in each case.
"CTH is very early in the game with a very good and relatively derisked idea."
The Life Science Report with Ori Hershkovitz